The objective of the Genetically Engineered Mouse (GEM) Resource is to aid Cancer Center investigatorswith the design and execution of experiments to utilize animal models for the investigation of the progressionof cancer and for the preclinical evaluation of therapies for the treatment of cancer. Although the use ofanimal models provides an invaluable source of reagents for preclinical testing and the investigation ofregulatory mechanisms in vivo in a physiologically regulated system, the use of animals is costly with respectto equipment, animal resources, and technical expertise. The GEM Core will serve as a resource forcarrying out and training in the use of all animal manipulations needed in the Cancer Center. The GEM Corewill minimize the cost of utilizing animal models in the Cancer Center by consolidating the equipment,expertise, and animal resources. This will ensure an efficient use of animal research at minimal cost.The GEM Core will serve Cancer Center investigators by aiding in the following tasks.1. The GEM Core will generate transgenic mice by the micro injection of DMA into one-celled mouseembryos.2. The GEM Core will generate mutant mice by the manipulation of mouse Embryonic Stem Cells.3. The Core will preserve lines of mice by cryopreservation.4 The Core will aid investigators with the importation and exporting of lines of mice.The accomplishments of these tasks will allow the GEM Core to serve as a repository for all geneticallyengineered mouse models and techniques for Cancer Center investigators and will ensure efficient use ofanimal resources by Cancer Center investigators. The Shared Resource Leader is Dr. Francesco DeMayo,who has an extensive track record in these areas

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
1P30CA125123-01
Application #
7514629
Study Section
Subcommittee G - Education (NCI)
Project Start
2007-07-01
Project End
2010-06-30
Budget Start
2007-07-01
Budget End
2008-06-30
Support Year
1
Fiscal Year
2007
Total Cost
$83,853
Indirect Cost
Name
Baylor College of Medicine
Department
Type
DUNS #
051113330
City
Houston
State
TX
Country
United States
Zip Code
77030
Kundu, Samrat T; Grzeskowiak, Caitlin L; Fradette, Jared J et al. (2018) TMEM106B drives lung cancer metastasis by inducing TFEB-dependent lysosome synthesis and secretion of cathepsins. Nat Commun 9:2731
Kim, Myunghoo; Galan, Carolina; Hill, Andrea A et al. (2018) Critical Role for the Microbiota in CX3CR1+ Intestinal Mononuclear Phagocyte Regulation of Intestinal T Cell Responses. Immunity 49:151-163.e5
Mamonkin, Maksim; Mukherjee, Malini; Srinivasan, Madhuwanti et al. (2018) Reversible Transgene Expression Reduces Fratricide and Permits 4-1BB Costimulation of CAR T Cells Directed to T-cell Malignancies. Cancer Immunol Res 6:47-58
Morriss, Ginny R; Rajapakshe, Kimal; Huang, Shixia et al. (2018) Mechanisms of skeletal muscle wasting in a mouse model for myotonic dystrophy type 1. Hum Mol Genet 27:2789-2804
Lanza, Denise G; Gaspero, Angelina; Lorenzo, Isabel et al. (2018) Comparative analysis of single-stranded DNA donors to generate conditional null mouse alleles. BMC Biol 16:69
Jeong, Mira; Park, Hyun Jung; Celik, Hamza et al. (2018) Loss of Dnmt3a Immortalizes Hematopoietic Stem Cells In Vivo. Cell Rep 23:1-10
Boudreaux, Seth P; Duren, Ryan P; Call, Steven G et al. (2018) Drug targeting of NR4A nuclear receptors for treatment of acute myeloid leukemia. Leukemia :
Sukumaran, Sujita; Watanabe, Norihiro; Bajgain, Pradip et al. (2018) Enhancing the Potency and Specificity of Engineered T Cells for Cancer Treatment. Cancer Discov 8:972-987
Kaochar, Salma; Mitsiades, Nicholas (2018) A Novel Mechanism to Drive Castration-Resistant Prostate Cancer. Trends Endocrinol Metab 29:366-368
Johnston, A N; Bu, W; Hein, S et al. (2018) Hyperprolactinemia-inducing antipsychotics increase breast cancer risk by activating JAK-STAT5 in precancerous lesions. Breast Cancer Res 20:42

Showing the most recent 10 out of 991 publications